Study Confirms Optimal Therapy Sequence for Rare Aggressive Lymphomas

Overview

• A Mass General Brigham-led study using PETAL Consortium data analyzed 12 treatment sequences for relapsed/refractory T- and NK-cell lymphomas.
• Findings confirm that second-line small molecule inhibitors followed by third-line epigenetic modifiers significantly improve survival outcomes.
• High-risk patients, including those with angioimmunoblastic T-cell lymphoma, showed the most pronounced survival benefits.
• The study employed machine learning models and stability analyses to provide robust evidence for targeted therapies over conventional chemotherapy.
• Published in the British Journal of Haematology, the research underscores the need for clinical trials and further investigation into agents like duvelisib.